The Clinical Trials Market in 2026

Start with the figure an investor will check first. The global clinical trials market was estimated at $89.0 billion in 2025 and is forecast to move from $94.0 billion in 2026 to $158.4 billion by 2033, a compound annual growth rate of 7.7% (Grand View Research, 2026). North America held 50.7% of that spend in 2025 (Grand View Research, US Clinical Trials Market), which matters when choosing between a US and a European launch market.

Headline growth is not the useful part. A clinical trials business sells capacity into specific therapeutic areas with very different growth profiles and per-patient economics. Three sub-markets worth pricing separately:

Sub-market figures: Grand View Research, Oncology Clinical Trials, Cell and Gene Therapy Clinical Trials and Cardiovascular Clinical Trials. Registry count: ClinicalTrials.gov Trends and Charts, 2026.

Who actually writes the cheques

Sponsors rarely contract directly with a new site. Almost all of the money reaches you through a contract research organisation, so your customer list is short, concentrated and public. Reported 2025 revenue: IQVIA's R&D Solutions segment at $8,896 million, ICON plc at $8,251.3 million, Thermo Fisher Scientific's clinical research business (formerly PPD) at $7,915 million, Fortrea at $2,723.4 million, Medpace up about 20% to $2.53 billion, and Parexel near $3.8 billion (IntuitionLabs, CRO Market Share 2026). CRO services market estimates for 2025 run from $85.4 billion (MarketsandMarkets) to roughly $92 billion (Straits Research).

A plan naming six target CROs, the therapeutic areas each runs heavily and the feasibility contact route into each reads as a commercial plan. "We will market to pharmaceutical sponsors" reads as a hope. Use the registry to show which of them already run studies in your indication within 100 miles of your site.

The demand-side tailwind investors will not know about

If you are launching in the UK, there is a policy tailwind worth a paragraph. Lord O'Shaughnessy's independent review of UK commercial clinical trials produced 27 recommendations, proposed quadrupling participants in commercial trials by 2027, and described a target of at least 20% of global recruitment by 2030 as plausible (GOV.UK, Government Response to the O'Shaughnessy Review). With the April 2026 regulatory reform, that supports an argument that UK site capacity is undersupplied against forecast demand: a structural opening rather than a share-stealing plan.

Why sponsor budgets set your ceiling

Average study cost by phase runs roughly $3.8 million for Phase I, $13.35 million for Phase II and $19.89 million for Phase III across therapeutic areas (Abacum, Trial Phase Costing Benchmarks). A site captures a low single-digit percentage of one study's budget, so model revenue from the protocols you can run concurrently and the per-patient grant in your indication, never as a share of a market-size number.

Consolidation is the other structural fact to address. GHO Capital acquired Velocity Clinical Research, a move the buyer framed as a signal of how the trial-site industry is evolving (GHO Capital, 2025), and Headlands Research moved from KKR to THL Partners (Fierce Biotech), reaching 22 sites after acquiring CMRCenter in San Juan in July 2025. Two consequences belong in your plan: there is an acquisition exit with observable comparables, and a single site competing on price against a 22-site network will lose. You need a reason a sponsor picks you: a patient population, a sub-specialty, or an activation-speed commitment a network cannot match.

Three Businesses That All Call Themselves Clinical Trials

Before you write a single financial assumption, decide which of three distinct businesses you are building. They share vocabulary and share nothing else: different capital, different licences, different customers and wildly different gross margins. Most failed plans we see are a blend of all three, which means no single section is costed correctly.

Ranges in the table are Avvale build estimates derived from the benchmarks cited below, not survey data. Replace them with quotes from your own landlord, vendors and insurers before submitting anything to a lender. A fourth model keeps getting reinvented: the decentralised or hybrid operator, where visits happen at home or at a pharmacy rather than a fixed site. Science 37 built its position on virtual trials reaching patients site-based models never see, with a capital profile closer to software plus a mobile nursing network.

Picking one and committing

The practical test is where your unfair advantage sits. A consultant hepatologist with a 4,000-patient list and six years as a sub-investigator should build a research-embedded practice first, then convert to a dedicated site once three protocols run concurrently. A former CRO start-up lead with regulatory depth but no patients should sell the function, not the site. A founder with capital but neither patients nor regulatory experience is buying a job in the hardest version of this business. Our market research and content package exists largely to settle this with catchment data before capital goes into the wrong model.

What It Costs to Stand Up a Trial Site

Published benchmarks for site start-up measure the wrong thing for a founder. The figures sponsors quote, around $20,000 plus $2,000 a month per study, or non-refundable start-up fees of roughly $5,000 rising to $8,000–$11,500, with administrative start-up fees of $12,000 for interventional studies and $7,500 for observational or registry work (IntuitionLabs, Clinical Trial Start-Up Costs), describe what it costs to activate one protocol at an existing site. They say nothing about building the site. The two differ by roughly an order of magnitude, and conflating them is the most common costing error in a clinical trials business plan.

Below is a build estimate for a single interventional site: three exam rooms, a monitor workroom, locked investigational product storage, two to three coordinators, a part-time principal investigator. It is a composite from the benchmark anchors cited here, vendor list pricing and our own client build-outs. Replace each line with a quote before you take it to a bank.

Two lines usually get cut by first-time founders, and both cuts are fatal. The first is the working-capital buffer, covered in the economics section below. The second is pre-revenue payroll: you cannot pass a sponsor site-qualification visit without a trained coordinator in post and signed SOPs on the shelf, so you pay salaries for months before a single start-up fee arrives. A plan showing revenue in month two is not optimistic, it is a credibility problem.

Payroll is the whole business, so cost it properly

The US Bureau of Labor Statistics does not publish a standalone occupation for clinical research coordinators. It maps them into Natural Sciences Managers, SOC code 11-9121, where the May 2025 Occupational Employment and Wage Statistics median sits at $167,220, with the 25th percentile at $119,430 and the 75th percentile at $221,540 (CareerOneStop / BLS OEWS, May 2025; see also the BLS Occupational Outlook Handbook). That bundles senior research managers with bench-level coordinators, so the median overstates what a community site pays an entry coordinator. Cite it for a research manager, not for your first two hires. Model four roles rather than one blended "staff" line:

• Principal investigator. Usually a stipend or sessional payment, because the PI retains clinical income. Budget a fraction of FTE and write the attestation duties into the job description so the time is defensible under audit.
• Clinical research coordinator. Your enrollment engine. Each carries roughly two to four protocols depending on visit intensity, the single most important capacity assumption in your forecast.
• Regulatory and start-up lead. Owns the investigator site file, IRB or REC submissions, deviation reporting and inspection readiness.
• Phlebotomy and processing support. Part-time at launch. Cheap to hire, expensive to skip: mishandled specimens become queries, and queries delay payment.

Institutional overhead benchmarks are a sanity check on your indirect-cost assumption, because sponsors negotiate against them. Published rates include Georgetown at 35% effective 1 February 2025, UCLA raised from 26% to 33% on 1 October 2024, UC Davis at 32% and SIU School of Medicine at 31% (IntuitionLabs, Site Payment Benchmarks 2026). Sites commonly require as much as 30% administrative overhead on top of the per-patient grant. Quote 15% to look competitive and you have donated the difference.

Monitors inspect physical specifics, so name them: examination rooms with a bed, a locked temperature-logged area for investigational product, secure record storage, a dedicated monitor workspace with its own network access, and a laboratory area with centrifuge and freezer. Store investigational product in a shared practice fridge and you will fail qualification.

Funding Routes: SBA Debt, UK Guarantees, Angel Money

A clinical trials business is an awkward borrower. It has real equipment and a lease, which lenders like, but its receivables sit with large counterparties on long terms, which lenders price as risk.

United States: SBA 7(a) and 504

In fiscal year 2025 the SBA approved 65,154 7(a) loans totalling $32.43 billion, an average of $497,789, with a median of $195,000 that better represents a typical approval. Healthcare and medical services consistently sit in the highest approval bands, roughly 72% to 80% for qualified applicants (SBA loan statistics compilation, 2026). That median shapes how you structure the ask: $190,000 of 7(a) working capital and equipment finance sits inside the normal distribution of approvals, while $900,000 routes to a heavier credit process.

Match the instrument to the asset: 7(a) for working capital, equipment, leasehold improvements and the pre-revenue payroll bridge, 504 only if you are buying the building. Classify carefully, because the code drives the size standard, the eligibility test and the underwriter's comparables. NAICS 541715 (Research and Development in the Physical, Engineering and Life Sciences) fits a standalone research site or specialist CRO; NAICS 621511 (Medical Laboratories, SBA size standard $41.5 million in average annual receipts) fits a site running its own specimen analytics; NAICS 621111 (Offices of Physicians) fits research inside an existing practice.

What the credit committee actually tests

• Contracted versus projected revenue. One executed clinical trial agreement with a named CRO beats twelve letters of interest. Put signed confidentiality agreements and completed feasibility questionnaires in the appendix.
• Debt service through the receivables trough. Month-by-month cash across the first 18 months, with sponsor payments landing on realistic terms rather than on invoice date.
• Key-person dependency. If the owner is also the only qualified investigator, the lender is underwriting one person's licence. Name a back-up investigator.
• Collateral coverage. Freezers, centrifuges and ECG units hold resale value; leasehold improvements do not. Expect to pledge personal assets on the gap.
• Enrollment evidence. Catchment population, registry density of competing studies, referral agreements and indication-specific screen-failure rates. Assertion without arithmetic is the most common reason a trials plan is declined.

United Kingdom and Europe

The UK stack looks different. British Business Bank Start Up Loans are personal loans to directors with mentoring attached, which works for a lean research-embedded launch but not a full site build. Growth Guarantee Scheme-backed term debt through a participating bank is the realistic route for a six-figure build, because the guarantee is what makes a lender comfortable with the receivables profile. Innovate UK competitions are worth pursuing only if you are genuinely innovating in methodology, recruitment technology or decentralised delivery. Confirm current scheme terms with the provider before building them into a forecast.

Equity has a specific role. Angel money suits the pre-revenue payroll bridge and the working-capital buffer, the two lines debt providers dislike most, because the investor is buying the enterprise value that appears when the third concurrent protocol starts. SEIS and EIS relief makes that round easier to close in the UK, and the consolidation above gives an angel a credible exit narrative. Pair a modest equity round against the soft costs with asset-backed debt against the hard costs and the package becomes financeable. Our bespoke business plan service builds the forecast in that split form so one model serves both conversations.

Site Economics: Grants, Start-Up Fees, Screen Failures

Four revenue streams, and almost every founder models only one of them.

• Study start-up fee. One-time per protocol, covering regulatory submission, site qualification, training and system build. Typically $2,000 to $20,000, interventional work at the top of the band and observational at the bottom. A Phase III cardiology study at an academic hospital has been described with an $18,000 to $30,000 start-up fee (Physician Side Gigs).
• Per-patient grant. The core line. $3,000 to $20,000 and above per randomised subject, delivered as visit-based payments of roughly $500 to $5,500 per completed visit. Average revenue per patient runs around $7,500 for sites enrolling 50 to 75 patients a year (IntuitionLabs, Site Payment Benchmarks 2026).
• Screen-failure payments. For subjects screened but not randomised, commonly $500 to $5,000 each. Not a rounding error, as the data below shows.
• Invoiceables and pass-throughs. Imaging, central-lab courier, advertising, unscheduled visits, archiving, product destruction, pharmacy handling. Material in aggregate, and the first thing a weak negotiator gives away.

Per-patient grants have moved sharply in the site's favour: investigator grant costs rose roughly 133% to 175% between 2015 and 2025, with Phase I oncology per-patient grants moving from $30,000 to $40,000 up to $70,000 to $110,000 (IntuitionLabs). Benchmark against a colleague's five-year-old contract and you are negotiating off a stale anchor.

Worked example: a three-room site in year two

Composite model for a single site running six concurrent protocols with three coordinators. Figures are illustrative and built from the benchmarks cited above.

Read the sensitivity, not the result. Drop from six protocols to three and revenue roughly halves while payroll, rent and subscriptions barely move. The cost base is a step function and the revenue is a volume function, which is why active research practices report annual research revenue anywhere from $50,000 to $800,000 and above, with established multi-protocol sites clearing $1 million, rather than clustering around a norm (Physician Side Gigs). Show the protocol count at which you cross break-even, and what happens if you get there two quarters late.

The receivables problem that closes sites

Here is the number that belongs on the first page of your financial summary and almost never appears. Shifting a site from monthly to quarterly sponsor payment terms extends the accounts receivable cycle from an average of 45 days to 137 days, while the site still faces biweekly payroll and monthly rent. Nearly 80% of sites carry less than six months of operating capital and 38% saw profit decline in 2023 (Society for Clinical Research Sites). At the worked example's $646,150 of annual revenue, a 137-day cycle parks roughly $243,000 in unpaid invoices at any moment, more than the whole equipment and fit-out budget at the low end of the capital table. Three contract terms change this and all three are negotiable at clinical trial agreement stage: the size and timing of the start-up fee, payment frequency, and whether screen failures are reimbursed at a defined rate rather than at the sponsor's discretion. Negotiating those well is worth more to a new site than a 10% uplift on the per-patient grant.

Enrollment is the variable that decides everything

Sponsors do not pay for capacity, they pay for randomised subjects, which makes enrollment risk the real content of your revenue forecast. The average screen-failure rate across all studies and therapeutic areas has reached 36.3%, up from 34.7% in 2012. One in ten investigator sites ready to recruit never enrolls a single patient, and 48% of all sites selected for a trial either enroll nobody or under-enroll. In rare disease, 81% of screened patients are ineligible and 56% of volunteers are never randomised (Applied Clinical Trials). Separately, 85% of trials hit screen-failure-related setbacks, and Tufts CSDD research puts the sponsor's cost of delay at roughly $800,000 of lost drug sales per day (DataAlly enrollment statistics).

Turn those into planning inputs. Forecast 68 randomised subjects at a 36% screen-failure rate and you need to screen roughly 106 and pre-screen several hundred. Work backwards from your catchment: list size or registry prevalence, consent rate, indication-specific screen-failure rate, retention through the final visit. Then size the recruitment budget against that funnel. The sponsor's delay cost is also your pitch: a site that can evidence a screening funnel sells schedule certainty.

Regulatory Clearance in the US, UK and EU

Clinical trials regulation is not a business-licence checklist, which is where generic templates fail hardest. Most of the approvals below sit with the sponsor rather than with you, but your site cannot receive a subject until every one is in place, so the sequence drives your revenue timing. Build it as a dated schedule, not a list.

United States

• Investigational New Drug application, 21 CFR Part 312. Filed by the sponsor. A 30-day review clock runs before the first subject may be dosed. No FDA filing fee, though outsourced regulatory authoring commonly runs $15,000 to $75,000.
• Form FDA 1572, Statement of Investigator. The investigator's signed agreement to comply with the regulations governing the investigation. It identifies the facility, the clinical laboratories used and the reviewing IRB, and must reach FDA within 30 days of an investigator being added to a study (FDA Information Sheet Guidance for Sponsors, Clinical Investigators and IRBs). This is the document that makes your address a registered trial site.
• IRB review and approval. Required before a study under an IND may be initiated, under 21 CFR 56.101 and 56.102(c). Central providers such as Advarra and WCG review commercial protocols in roughly two to six weeks, with initial fees commonly in the low thousands per protocol plus continuing review. For NIH-funded multi-site work, a single IRB of record is the default.
• Federalwide Assurance with the HHS Office for Human Research Protections. No fee, needed for federally supported human-subjects research. It is free and removes a gating item, so get it before you need it.
• CLIA certification and DEA registration, where applicable. CLIA if you analyse specimens on site rather than shipping to a central laboratory. DEA registration if the investigational product is a scheduled substance, which also drives storage and dispensing-record requirements.
• 21 CFR Part 11 and HIPAA. Every electronic system holding source data, consent or regulatory documents must support validated records and signatures with an audit trail. That is why the technology line in your capital table is non-discretionary.
• Ordinary business compliance. State registration, EIN, professional and clinical trial liability cover, and employment compliance for a workforce handling protected health information.

United Kingdom

The UK changed materially in 2026 and plans written against the old framework now read as out of date. Every clinical trial of an investigational medicinal product goes through combined review: one application assessed jointly by the MHRA and a Research Ethics Committee, coordinated by the Health Research Authority, with a statutory requirement to reach a decision within 30 days of validation (GOV.UK, Clinical trials for medicines: apply for authorisation in the UK).

• The new rules, in force 28 April 2026. The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 came into force on 28 April 2026, and every application submitted on or after that date is assessed under the updated framework (Health Research Authority, Clinical trials regulations reform). Quote pre-2026 timelines and a reviewer with sector knowledge will discount your whole regulatory section.
• The 14-day notification pathway. Where a trial meets the eligibility criteria, typically lower-risk studies of a licensed medicine used within or close to its licensed indication, the MHRA confirms automatic authorisation within 14 calendar days rather than running the standard 30-day assessment (Jones Day, UK Clinical Trials Enter a New Regulatory Era). For a site positioning on activation speed, knowing which of a sponsor's studies qualify is a real commercial advantage.
• HRA Approval and site capacity and capability. HRA Approval covers study-wide governance. Each participating organisation then confirms its own capacity and capability to deliver, which is where timelines slip rather than at the regulator.
• Named sponsor. Every UK trial needs a legal sponsor, and a non-UK sponsor needs a UK legal representative. If you intend to sponsor investigator-initiated studies yourself, the pharmacovigilance and insurance obligations are a separate cost centre.
• MHRA GCP inspection readiness and CQC registration. Inspection readiness is continuous, not an event. Where your site delivers regulated activities, Care Quality Commission registration applies, typically ten to fourteen weeks.

European Union

The EU route changed earlier and more completely. Regulation (EU) 536/2014 replaced country-by-country submissions with a single dossier filed in the Clinical Trials Information System, valid across every participating member state. Assessment splits into Part I, the scientific evaluation at EU level, and Part II, the national and ethical evaluation, with windows of 45 days each and a maximum of 60 days for an initial decision. All ongoing trials had to transition into CTIS by 31 January 2025 (Advarra, Understanding the EU Clinical Trials Regulations Updates).

Sponsors now assemble multi-country packages and compare member states on the predictability of Part II timelines and on activation speed, so a site in a slow-assessing member state competes at a disadvantage regardless of capability. If Canada is in scope, Health Canada operates a Clinical Trial Application with a 30-day default review alongside Research Ethics Board approval and a Qualified Investigator attestation per site. Whichever jurisdictions you name, do the same three things for each: name the authorisation, name the body, state the clock.

The Site Technology Stack

Sponsor qualification questionnaires ask what systems you run, and "spreadsheets and a filing cabinet" ends the conversation, because the sponsor is accountable for data integrity and electronic-records compliance across your site. Name the products you intend to buy, with price anchors.

• Clinical trial management system (CTMS). Protocol, subject, visit and finance tracking in one place. RealTime-CTMS is the common choice for independent commercial sites, with list pricing from around $295 per month and modules for site payments and participant text messaging. Advarra OnCore serves larger programmes and academic centres, bundling eRegulatory, eConsent, eSource and EDC in 21 CFR Part 11-compliant systems. Veeva Vault CTMS and Oracle Clinical One sit on the sponsor side; you interact with them, not buy them.
• eRegulatory and the electronic investigator site file. Complion, a RealTime Software Solutions subsidiary, and Florence eBinders are the names monitors recognise. The value is the audit trail, not storage: version control, delegation logs, training-record expiry and signature capture. A paper site file is legal and the fastest route to a finding.
• eSource and electronic data capture. Clinical Research IO (CRIO) is the site-side platform most independents standardise on, recording visit data at the point of care so it reconciles into the sponsor's EDC, usually Medidata Rave. Direct-to-EDC entry without a source layer is where query volume accumulates.
• Participant payments and logistics. Greenphire ClinCard and RealTime-PAY handle stipends without your finance team cutting cheques, which measurably affects retention. Suvoda and comparable platforms manage randomisation and product supply on sponsor instruction. StudyTeam by Reify Health matters because sponsors increasingly ask sites to report pipeline through it.

Pricing is per-site, per-user and per-module, so list prices are an anchor rather than a quote. A realistic year-one budget for an independent three-room site is the $3,500 to $30,000 band in the capital table, and it is near-fixed: it does not fall when enrollment stalls.

Mistakes that show up in the first audit

• Budgeting the fit-out and not the receivables cycle. The P&L shows profit in month seven while the bank account fails in month five. The most common cause of death for an otherwise well-run site.
• Signing a clinical trial agreement with no screen-failure clause. At a 36.3% average screen-failure rate, unreimbursed screening is a direct subsidy from you to the sponsor.
• Promising enrollment the catchment cannot supply. With 48% of selected sites enrolling nobody or under-enrolling, sponsors discount site-supplied estimates by default. Under-delivery costs you the next protocol.
• Running a single protocol and calling it a business. Coordinator, regulatory and subscription costs only amortise across three or more concurrent studies. Plan the third before the first activates.
• Leaving the temperature log on paper. One unlogged excursion becomes a deviation, a query cycle and potentially excluded subject data, far more expensive than the monitoring system you declined to buy.

Sample Business Plan Extract

Below is an extract from a clinical trials business plan in the format our consultants deliver. The company is a composite, not a real client.

Download Free Template Premium Template - $5 / GBP5

What You Get Inside the Template

The clinical trials edition of our template is structured so each section answers a question a lender, a sponsor or an investor will actually ask.

• Executive summary built to the structure in the extract above, with the capital ask, break-even protocol count and peak cash month on the first page.
• Business model selection worksheet covering dedicated site, research-embedded practice, functional specialist and decentralised operator.
• Market and sponsor-demand section with prompts for registry-derived competitive density and a named target list of contract research organisations.
• Feasibility and enrollment model: catchment population, consent rate, indication-specific screen-failure rate, retention, and the screened-to-randomised ratio that drives your recruitment budget.
• Capital schedule matching the ten-line structure in this guide, with separate columns for quote received, quote pending and estimate.
• Revenue build by protocol: start-up fee, per-patient grant, screen-failure reimbursement and invoiceables, with a protocol-count sensitivity.
• Five-year financial statements: profit and loss, balance sheet, monthly cash flow for year one and quarterly thereafter, with the receivables cycle modelled explicitly.
• Regulatory schedule as a dated Gantt covering IND or CTA timing, IRB or REC review, site activation and first subject in, for each jurisdiction you operate in.
• Operations and quality plan: SOP index, delegation log, training matrix, investigational product handling, temperature excursion procedure, inspection readiness.
• Technology plan naming your CTMS, eRegulatory, eSource and payments systems with validation status and cost.
• Risk register and appendix structure covering enrollment, payment timing, key-person and competitive risks, plus executed agreements, feasibility questionnaires, CVs, GCP certificates, floor plan and equipment list.

If you would rather not assemble it yourself, a professional business plan writer on our team can build the feasibility model and the forecast with you. Related guides worth reading alongside this one: our clinical research business plan template covers the broader research-services business, clinical trial supplies covers the logistics and comparator-sourcing side, and clinical diagnostics covers laboratory-led models.

Clinical Trials Business Plan Questions

Useful Links & Resources

These links were preserved from the live page so important references and partner links are not lost during the page refresh.

• Facebook
• Instagram
• LinkedIn
• YouTube